Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles

British Journal of Cancer

Volumn 97, Issue 12, 2007, Pages 1648-1654

  Naito, M ^a   Komohara, Y ^a   Ishihara, Y ^a   Noguchi, M ^a   Yamashita, Y ^b   Shirakusa, T ^b   Yamada, A ^a   Itoh, K ^a   Harada, M ^a,c  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIMANE UNIVERSITY   (Japan)

Author keywords

Cytotoxic T lymphocyte; HLA A3 supertype; Lck; Peptide

Indexed keywords

CANCER VACCINE; HLA A ANTIGEN; HLA A11 ANTIGEN; HLA A3 ANTIGEN; HLA A31 ANTIGEN; HLA A33 ANTIGEN; IMMUNOGLOBULIN G; ISOLEUCYLGLUTAMINYLASPARAGINYLLEUCYLGLUTAMYLARGINYLGLYCYLTYROSYLARGININE; ISOLEUCYLLEUCYLGLUTAMYLGLUTAMINYLSERYLGLYCYLGLUTAMYLTRYPTOPHYL TRYPTOPHYLLYSINE; PEPTIDE; PROTEIN KINASE LCK; UNCLASSIFIED DRUG; VALYLISOLEUCYLGLUTAMINYLASPARAGINYLLEUCYLGLUTAMYLARGINYLGLYCYL TYROSYLARGININE;

ALLELE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER PATIENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG POTENCY; HLA TYPING; HUMAN; HUMAN CELL; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN MOTIF;

CANCER VACCINES; CELL LINE, TUMOR; HLA-A3 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MALE; NEOPLASMS; PEPTIDES; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 37049013506     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604071     Document Type: Article

References (26)

1. Aizawa M (1986) The Proceedings of the 3rd Asia-Oceania Histocompatibility Conference pp 1090-1103. Oxford: Oxford University Press
2. Amundadottir LT, Leder P (1998) Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16: 737-746
3. + prostate cancer patients. Oncol Rep 12: 601-607
4. Harashima N, Tanaka K, Sasatomi T, Shimizu K, Miyagi Y, Yamada A, Tamura M, Yamana H, Itoh K, Shichijo S (2001) Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 31: 323-332
5. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K (2002) A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51: 219-228
6. Imai N, Harashima N, Ito M, Miyagi Y, Harada M, Yamada A, Itoh K (2001) Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases. Int J Cancer 94: 237-242
7. Imanishi T, Akazawa T, Kimura A (1992) Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In HLA 1991, Tsuji K, Aizawa M, Sasazuki T (eds), vol. 1, pp 1065-1220. Oxford: Oxford Scientific Publications
8. Komatsu N, Shichijo S, Nakagawa M, Itoh K (2004) New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 64: 535-545
9. Krystal GW, DeBerry CS, Linnekin D, Litz J (1998) Lck associates with and is activated by kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res 58: 4660-4666
10. Lutz MP, Eber IBS, Flossmann-Kast BBM, Vogelmann R, Luhrs H, Friess H, Buchler W, Adler G (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243: 503-508
11. lck). Mol Cell Biol 8: 540-550
12. Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K, Harada M (2005) Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 11: 6933-6943
13. lck from type I promoter transcript in colon carcinoma. Oncogene 15: 2929-2937
14. Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M (2007) Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 56: 689-698
15. Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shoumura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H (2004) Humoral responses to peptides correlated with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10: 929-937
16. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K (2002) Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 32: 826-836
17. Ohkouchi S, Yamada A, Imai N, Mine T, harada K, Shichijo S, Maeda Y, Saijo Y, Nukiwa T, Itoh K (2002) Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. Tissue Antigens 59: 259 -272
18. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152: 163-175
19. Rammensee HG, Friege T, Stevanovics S (1995) MHC ligands and peptides motifs. Immunogenetics 41: 178-228
20. Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15
21. Robinson D, He F, Pretlow T, Kung HJ (1996) A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 93: 5958-5962
22. Sato Y, Shomura H, Maeda Y, Mine T, Ueno Y, Akasaka Y, Kondo M, Takahashi S, Shinohara T, Katagiri K, Sato M, Okada S, Matsui K, Yamada A, Yamana H, Itoh K, Todo S (2003) Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94: 802-808
23. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 201-212
24. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, del Guercio MF, Kubo RT, Chestnut RW, Sette A (1996) Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 45: 79-93
25. lck. Nature 338: 257-259
26. Yamada A, Itoh K (2006) Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 97: 970-976